title: Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?
abstract: BACKGROUND
  Vascular endothelial growth factor (VEGF) is one of the most important angiogenic factors in solid tumours and plays an important role in ascites development in peritoneal surface malignancies (PSM). The main goal of this study was to determine the evolution and factors influencing intraperitoneal (IP) VEGF burden during cytoreductive surgery (CRS) with curative intent.
  
  
  METHODS
  Ninety-seven consecutive patients with PSM were treated with CRS at a single centre with curative intent. Patient data were collected prospectively between February 2012 and October 2012. An enzyme-linked immunosorbent assay technique was used to assess VEGF levels in intravenous (IV) systemic blood samples before incision and after abdominal closure, and in IP samples during abdominal cavity exploration, after completion of CRS, after hyperthermic IP chemotherapy, and at 1 and 24h after abdominal closure.
  
  
  RESULTS
  The IP VEGF burden increased significantly after CRS, and then decreased progressively (p<0.005). In multivariate analysis, neoadjuvant IV bevacizumab significantly decreased the preoperative IP VEGF burden, tumour load according to Peritoneal Cancer Index value increased significantly the preoperative IP VEGF burden and a low preoperative IP VEGF burden was associated with significantly increased postoperative complications. Neoadjuvant IV bevacizumab is the only factor that influences the preoperative IV VEGF concentration.
  
  
  CONCLUSIONS
  For patients with PSM who were treated with curative intent, the IP VEGF burden increased after CRS, and was reduced prior to surgery by the administration of neoadjuvant IV bevacizumab.
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38, Université Lyon 1, Lyon, France. Electronic address: guillaume.passot@chu-lyon.fr.
authors.forename: G
authors.initials: G
authors.lastname: Passot
authors.affiliation: UMR 37-38, Université Lyon 1, Lyon, France; Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Gynecology Department, France.
authors.forename: N
authors.initials: N
authors.lastname: Bakrin
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Biology, France.
authors.forename: L
authors.initials: L
authors.lastname: Garnier
authors.affiliation: Hospices Civils de Lyon, Pole IMER, Lyon, France; Health Information and Clinical Research, France.
authors.forename: A
authors.initials: A
authors.lastname: Roux
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France.
authors.forename: D
authors.initials: D
authors.lastname: Vaudoyer
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Anaesthesiology, France.
authors.forename: F
authors.initials: F
authors.lastname: Wallet
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38, Université Lyon 1, Lyon, France.
authors.forename: F N
authors.initials: FN
authors.lastname: Gilly
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38, Université Lyon 1, Lyon, France.
authors.forename: O
authors.initials: O
authors.lastname: Glehen
authors.affiliation: Hospices Civils de Lyon, Centre Hospitalier Lyon Sud Pierre Bénite, Department of Oncologic and General Surgery, France; UMR 37-38, Université Lyon 1, Lyon, France.
authors.forename: E
authors.initials: E
authors.lastname: Cotte
mesh_terms: D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage*; D001201:Ascites / Q000378:metabolism; D000068258:Bevacizumab; D003131:Combined Modality Therapy; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D006801:Humans; D007274:Injections, Intraperitoneal; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D010534:Peritoneal Neoplasms / Q000188:drug therapy* / Q000378:metabolism* / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D011553:Pseudomyxoma Peritonei / Q000188:drug therapy / Q000378:metabolism / Q000473:pathology / Q000601:surgery; D012074:Remission Induction; D042461:Vascular Endothelial Growth Factor A / Q000032:analysis / Q000276:immunology / Q000378:metabolism*
chemical_list: D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab
keywords: Cytoreductive surgery; Intraperitoneal VEGF; Peritoneal carcinomatosis